◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

TEVOGEN BIO HOLDINGS INC.

CIK: 1860871 SIC: 2836
-
Revenue
$-31.04M
Net Income
-
Gross Margin
-
Op. Margin
$-23.00M
Free Cash Flow
Financial Statements Annual (10-K)
Showing 4 of 4 annual reports available (2021 - 2024)
Breakdown TTM
(Sep 30, 2025)
FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
Operating Expenses $30.89M $53.56M $8.84M $953.08K -
Research & Development $11.84M $31.03M $4.40M - -
Operating Income $-30.89M $-53.56M $-8.84M - -
Interest Expense - $184.04K $256.03K - -
Other Income/Expense - - $2.21M $5.36M -
Net Income $-31.04M $-13.73M $-67.33K $4.41M -
Basic EPS -0.19 -0.07 -2.44 nan -
Diluted EPS -0.19 -0.07 -2.44 nan -
Basic Shares Outstanding 196.0M 146.7M 24.8M - -
Diluted Shares Outstanding 196.0M 146.7M 24.8M - -
Breakdown FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
Cash & Cash Equivalents $1.28M $8.84K $129.19K $344.58K
Other Current Assets $919.09K $2.50K $145.17K $446.61K
Total Current Assets $2.36M $355.84K $274.36K $791.19K
Property Plant & Equipment $296.44K $458.65K - -
Other Non-current Assets $575.84K $271.14K - -
Total Assets $3.46M $17.04M $357.14M $352.85M
Accounts Payable $5.20M $3.42M - -
Accrued Liabilities $1.71M $1.10M - -
Other Current Liabilities - $230.00K $140.00K -
Total Current Liabilities $9.04M $3.00M $350.45K $59.38K
Total Liabilities $10.14M $17.73M $15.06M $15.18M
Common Stock $17.80K $12.00K - -
Retained Earnings $-113.39M $-17.38M $-14.78M $-14.23M
Total Stockholders Equity $-6.67M $-17.38M $-14.78M $-14.23M
Total Liabilities & Equity $3.46M $17.04M $357.14M $352.85M
Breakdown TTM
(Sep 30, 2025)
FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
Net Income $-31.04M $-13.73M $-67.33K $4.41M -
Stock-based Compensation $38.56M $40.76M - - -
Operating Cash Flow $-23.00M $-12.00M $-1.38M $-215.40K -
Capital Expenditure - - $133.00K - -
Investing Cash Flow - - $342.92M - -
Stock Repurchased - - $342.98M - -
Financing Cash Flow $21.80M $12.23M $-341.66M - -
Net Change in Cash $-1.20M $230.60K $-4.43M - -
SEC Filing Format - Data shown as it appears in the Q3 2025 (10-Q) filing Period ended: Sep 30, 2025
Condensed Consolidated Statements of Operations
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Operating Expenses $5.73M - $21.53M -
Research & Development $3.11M - $9.01M -
Operating Income $-5.73M - $-21.53M -
Net Income $-5.73M $-9.66M $-21.60M -
Basic EPS -0.03 - -0.12 -
Diluted EPS -0.03 - -0.12 -
Basic Shares Outstanding $196.03M - $187.09M -
Diluted Shares Outstanding $196.03M - $187.09M -
Condensed Consolidated Balance Sheets
Description Sep 30, 2025 Dec 31, 2024
Cash & Cash Equivalents $1.04M $1.28M
Other Current Assets $925.82K $919.09K
Total Current Assets $2.12M $2.36M
Property Plant & Equipment $163.93K $296.44K
Other Non-current Assets $565.88K $575.84K
Total Assets $4.49M $3.46M
Accounts Payable $3.31M $5.20M
Accrued Liabilities $1.20M $1.71M
Total Current Liabilities $6.74M $9.04M
Total Liabilities $12.32M $10.14M
Common Stock $19.74K $17.80K
Retained Earnings $-134.98M $-113.39M
Total Stockholders Equity $-7.82M $-6.67M
Total Liabilities & Equity $4.49M $3.46M
Condensed Consolidated Statements of Cash Flows
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Net Income $-5.73M $-9.66M $-21.60M -
Stock-based Compensation - - $13.78M -
Operating Cash Flow - - $-10.15M -
Investing Cash Flow - - - -
Financing Cash Flow - - $9.90M -
Net Change in Cash - - $-245.90K -

All values are in USD (United States Dollars). Data is sourced from SEC EDGAR 10-K filings.

Annual data represents full fiscal year results. FY = Fiscal Year ending.

NEWS
Loading news...
TRENDING
Loading...